Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03040973
Title Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving INC280 Treatment as Single Agent or in Combination With Other Treatments.
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

Capmatinib + Nazartinib

Capmatinib

Capmatinib + Gefitinib

Age Groups: adult | child | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN

Facility Status City State Zip Country Details
Massachusetts General Hospital MGH Cancer Center Recruiting Boston Massachusetts 02114 United States Details
Novartis Investigative Site Recruiting Edmonton Alberta T6G 1Z2 Canada Details
Novartis Investigative Site Completed Copenhagen DK-2100 Denmark Details
Novartis Investigative Site Completed Dijon Cedex Cote D Or 21034 France Details
Novartis Investigative Site Withdrawn Dresden 01307 Germany Details
Novartis Investigative Site Recruiting Hannover 30625 Germany Details
Novartis Investigative Site Recruiting Koeln 50937 Germany Details
Novartis Investigative Site Recruiting Perugia PG 06129 Italy Details
Novartis Investigative Site Recruiting Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Withdrawn Seoul 05505 Korea, Republic of Details
Novartis Investigative Site Recruiting Singapore Singapore Details
Novartis Investigative Site Completed Madrid 28040 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field